Suppr超能文献

雄激素受体和 ERK 信号在雌激素受体阴性乳腺癌中的反馈回路。

A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.

机构信息

University of Queensland Diamantina Institute, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

出版信息

Neoplasia. 2011 Feb;13(2):154-66. doi: 10.1593/neo.101324.

Abstract

Estrogen receptor (ER)-negative breast cancer is heterogeneous, and the biology of this disease has remained poorly understood. Molecular apocrine is a subtype of ER-negative breast cancer that is characterized by the overexpression of steroid-response genes such as AR and a high rate of ErbB2 amplification. In this study, we have identified a positive feedback loop between the AR and extracellular signal-regulated kinase (ERK) signaling pathways in molecular apocrine breast cancer. In this process, AR regulates ERK phosphorylation and kinase activity. In addition, AR inhibition results in the down-regulation of ERK target proteins phospho-RSK1, phospho-Elk-1, and c-Fos using an in vivo molecular apocrine model. Furthermore, we show that AR-mediated induction of ERK requires ErbB2, and AR activity, in turn, regulates ErbB2 expression as an AR target gene. These findings suggest that ErbB2 is an upstream connector between the AR and ERK signaling pathways. Another feature of this feedback loop is an ERK-mediated regulation of AR. In this respect, the inhibition of ERK phosphorylation reduces AR expression and CREB1-mediated transcriptional regulation of AR acts as a downstream connector between the AR and ERK signaling pathways in molecular apocrine cells. Finally, we demonstrate that AR-positive staining is associated with the overexpression of ERK signaling targets phospho-Elk-1 and c-Fos in ER-negative breast tumors, which further supports a cross-regulation between the AR and ERK signaling pathways in molecular apocrine subtype. This study demonstrates an AR-ERK feedback loop in ER-negative breast cancer with significant biologic and therapeutic implications in this disease.

摘要

雌激素受体(ER)阴性乳腺癌是异质性的,其生物学特性仍知之甚少。分子大汗腺癌是 ER 阴性乳腺癌的一种亚型,其特征是甾体反应基因如 AR 的过度表达和 ErbB2 扩增率高。在这项研究中,我们已经确定了分子大汗腺癌中 AR 和细胞外信号调节激酶(ERK)信号通路之间的正反馈环。在此过程中,AR 调节 ERK 的磷酸化和激酶活性。此外,使用体内分子大汗腺癌模型,AR 抑制导致 ERK 靶蛋白磷酸化 RSK1、磷酸化 Elk-1 和 c-Fos 的下调。此外,我们表明 AR 介导的 ERK 诱导需要 ErbB2,并且 AR 活性反过来又作为 AR 靶基因调节 ErbB2 表达。这些发现表明 ErbB2 是 AR 和 ERK 信号通路之间的上游连接器。该反馈环的另一个特征是 ERK 介导的 AR 调节。在这方面,抑制 ERK 磷酸化减少 AR 表达,并且 CREB1 介导的 AR 转录调节作为 AR 和 ERK 信号通路之间的下游连接器在分子大汗腺细胞中起作用。最后,我们证明 AR 阳性染色与 ER 阴性乳腺癌中 ERK 信号靶标磷酸化 Elk-1 和 c-Fos 的过度表达相关,这进一步支持了分子大汗腺亚型中 AR 和 ERK 信号通路之间的交叉调节。这项研究在 ER 阴性乳腺癌中证明了 AR-ERK 反馈环,这对该疾病具有重要的生物学和治疗意义。

相似文献

7
Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.
Cancer Lett. 2010 Dec 1;298(1):74-87. doi: 10.1016/j.canlet.2010.06.005. Epub 2010 Jul 6.
8
Targeting androgen receptor in estrogen receptor-negative breast cancer.
Cancer Cell. 2011 Jul 12;20(1):119-31. doi: 10.1016/j.ccr.2011.05.026.
10
A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
Oncogene. 2010 Oct 28;29(43):5839-49. doi: 10.1038/onc.2010.318. Epub 2010 Aug 16.

引用本文的文献

1
Do AR and TILs have any association with the efficacy of neoadjuvant treatment for HER2-positive breast cancer?
Medicine (Baltimore). 2025 Sep 5;104(36):e44364. doi: 10.1097/MD.0000000000044364.
3
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities.
Nat Rev Cancer. 2025 Feb;25(2):93-108. doi: 10.1038/s41568-024-00772-w. Epub 2024 Nov 25.
4
Androgen receptor expression and clinical characteristics in breast cancer.
World J Surg Oncol. 2024 Sep 11;22(1):243. doi: 10.1186/s12957-024-03525-z.
6
Treatments Targeting the Androgen Receptor and Its Splice Variants in Breast Cancer.
Int J Mol Sci. 2024 Feb 2;25(3):1817. doi: 10.3390/ijms25031817.
7
Prognostic Role of Prolactin-Induced Protein (PIP) in Breast Cancer.
Cells. 2023 Sep 11;12(18):2252. doi: 10.3390/cells12182252.
9
Correlation between androgen receptor expression and pathological response rate in pre-operative HER2-positive breast cancer patients.
J Cancer Res Clin Oncol. 2023 Sep;149(12):10109-10117. doi: 10.1007/s00432-023-04904-x. Epub 2023 Jun 2.
10
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far.
Onco Targets Ther. 2023 Apr 7;16:235-247. doi: 10.2147/OTT.S379867. eCollection 2023.

本文引用的文献

2
Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.
Cancer Lett. 2010 Dec 1;298(1):74-87. doi: 10.1016/j.canlet.2010.06.005. Epub 2010 Jul 6.
3
BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer.
Mol Cancer. 2010 May 19;9:111. doi: 10.1186/1476-4598-9-111.
4
EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast.
Mod Pathol. 2010 May;23(5):644-53. doi: 10.1038/modpathol.2010.50. Epub 2010 Mar 5.
6
Expression of androgen receptors in primary breast cancer.
Ann Oncol. 2010 Mar;21(3):488-492. doi: 10.1093/annonc/mdp510. Epub 2009 Nov 3.
8
BEX2 regulates mitochondrial apoptosis and G1 cell cycle in breast cancer.
Int J Cancer. 2010 Apr 1;126(7):1596-610. doi: 10.1002/ijc.24866.
9
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Clin Cancer Res. 2009 Jul 15;15(14):4649-64. doi: 10.1158/1078-0432.CCR-09-0317. Epub 2009 Jun 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验